NewsHK
Against the backdrop of a semiconductor rally to open the trading week, Bristol Myers has moved to purchase new Nvidia chips to drive its artificial intelligence drug discovery program.
The pharmaceutical company's step into specialized AI hardware adds a demand signal from outside the traditional technology complex.
For a sector accustomed to tracking hyperscaler spending, the cross-border read-through here is that regulated industries are now competing for the same silicon.
Bristol Myers enters the AI hardware build The company is acquiring new Nvidia chips specifically for drug discovery work powered by artificial intelligence.
Keep reading